American Lung Association Makes Additional Investments in COVID and Respiratory Virus Research, Announces Second Call for Research Applications

As part of COVID-19 Action Initiative, American Lung Association’s research investment aims to help solve the coronavirus pandemic

The American Lung Association announced through its COVID-19 Action Initiative a second cycle for applications for its COVID-19 and Respiratory Virus Research Award. The award, which helps with the search for better COVID-19 and future respiratory virus treatments as well as explores a better scientific understanding of the virus, is funded at $100,000 a year for two years.

The COVID-19 and Respiratory Virus Research Award is part of the Lung Association’s recently expanded awards and grants program through its COVID-19 Action Initiative. Letters of Intent for this second application cycle are due February 18, 2021. Click here to apply.

“As COVID-19 persists in the United States, the American Lung Association remains deeply committed to its goal of helping to solve the coronavirus pandemic,” said American Lung Association President and CEO Harold Wimmer. “We received overwhelming interest in the first round from many brilliant researchers, and we’re pleased to fund so many promising research projects. In response to the tremendous need, we are extending our call for applications to address the pandemic and support and lives and health of Americans.”

As our world seeks to understand the virus and its impact on our health, including the complex immune response of the body to the virus which may result in massive and fatal inflammation, the need for research on COVID-19 and similar respiratory viruses is essential. The COVID-19 and Respiratory Virus Research Award helps researchers explore bold new approaches to treatment, such as developing antibodies to attack the virus.

The Lung Association welcomes applications for projects exploring COVID-19 that may help reduce the burden of COVID-19 in the U.S., including areas of focus such as the immune system’s response, how the virus causes pathology and applying public health to help identify risk factors and how we can reduce community spread.

These new research efforts are made possible through the American Lung Association’s COVID-19 Action Initiative, a $25 million investment in research, education, advocacy and coalition over the next three years with an aim to end COVID-19 and reduce the spread of future respiratory viruses. The COVID-19 Action Initiative will be used to provide free lung health education and masks to those in need, protect public health by advocating for COVID-19 and flu vaccines in underserved communities of color and prevent future outbreaks by investing in respiratory virus research.

In the initial round of funding for the Respiratory Virus Research awards announced on October 16 we funded $2.4 million for 12 awards exploring issues like the molecular analysis of antibody responses, controlling the immune response, risk factors for who might experience the most severe impacts of COVID-19 and much more.

For more information about the COVID-19 Action Initiative or the American Lung Association’s COVID-19 research award recipients and projects, visit and Meet our full research team including our current awardees and read the full abstracts of the American Lung Association research team at

For media seeking an interview with a COVID-19 researcher or lung health expert, contact Allison MacMunn at [email protected] or 312-801-7628.

For more information, contact:

Allison MacMunn
[email protected]

Freedom From Smoking Clinic
, | May 02, 2022
Freedom From Smoking Clinic
Virginia Beach, VA | May 10, 2022